🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Biontech Shares Drop Amid Pfizer’s Vaccine Write-Offs, Establishment Labs Gains on FDA Clearance

EditorVenkatesh Jartarkar
Published 10/16/2023, 11:54 AM
© Reuters.
HSIC
-
XLV
-
ESTA
-
BNTX
-

In the healthcare sector, several significant events unfolded on Monday. Shares of BioNTech (NASDAQ:BNTX) fell by more than 6% following the company's announcement of a projected Q3 negative impact of up to 900 million euros ($947.5 million). This downturn is linked to Pfizer (NYSE:PFE)'s write-offs and charges related to the Comirnaty COVID-19 vaccine.

Meanwhile, Henry Schein 's (NASDAQ:HSIC) stock decreased by over 2% due to a cybersecurity incident affecting its manufacturing and distribution units. The company is currently working to mitigate the situation and restore normal operations.

On a positive note, Establishment Labs Holdings' (NASDAQ:ESTA) shares rose above 4% after receiving FDA clearance for its Motiva Flora SmoothSilk tissue expander. This approval marks a significant milestone for the company in expanding its product portfolio.

In the broader market, the Health Care Select Sector SPDR Fund (NYSEARCA:XLV) advanced by 0.5% during pre-bell Monday, while the iShares Biotechnology ETF (NASDAQ:IBB) remained inactive. This movement indicates a mixed performance within the healthcare sector, with individual companies experiencing varied fortunes based on their recent developments.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.